Fundraising Fox
/People
Sign in

Peter Olagunju

Former Operating Partner at Catalio Capital Management, LP

Cambridge, Massachusetts, United States

Find your path to Peter

726 people in our graph can introduce you to Peter.

Each arrow is one introduction. Sign up to fill in the first one.

Ask Jim Caggiano to introduce you to Peter

You →Jim · together at Valeant Pharmaceuticals (2015) →Peter

Ask Jamie Chen to introduce you to Peter

You →Jamie · 2 people · together at Dendreon →Peter

Ask Sam Okafor to introduce you to Peter

You →Sam · together at Bluebird Bio →Peter

Sign up to find every way you can get introduced to Peter

  • Your email: the people you already email who know Peter
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with Peter
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

About

Peter Olagunju is CEO at a stealth-mode biotech company and serves as a board director. He has over 20 years of experience in clinical development, program management, manufacturing, quality management, and technical operations, spanning product types including small molecules, gene and cellular therapies, vaccines, recombinant proteins, monoclonal antibodies, and drug-device combinations. His work has contributed to advancing seven products from clinical development to commercialization, including ABECMA, ADSTILADRIN, LYFGENIA, PROVENGE, RECOTHROM, SKYSONA, and ZYNTEGLO.

Experience

  1. Stealth Mode BiotechCEOcurrent2024 — presentBoston, Massachusetts, United States
  2. March BiosciencesChairman of the Board of Directorscurrent2023 — presentHouston, Texas, United States
  3. The Just SocietyMember Board of Directors2024 — 2026
  4. Catalio Capital ManagementOperating Partner2024New York City Metropolitan Area
  5. Ollo, LLC.Principal & Owner2020 — 2024Cambridge, Massachusetts, United States
  6. TCR² Therapeutics Inc.Chief Operating Officer2022 — 2023Cambridge, Massachusetts, United States
  7. TCR² Therapeutics Inc.Chief Technology Officer2021 — 2022Cambridge, Massachusetts, United States
  8. TPGAdvisor2023San Francisco Bay Area
  9. BlackstoneAdvisor2021Cambridge, Massachusetts, United States
  10. FerGeneSenior Vice President, Technical Operations2020 — 2021Cambridge, Massachusetts, United States
  11. General AtlanticAdvisor2020 — 2021New York, United States
  12. bluebird bioVice President, Global Patient Operations2018 — 2020Cambridge, MA
  13. bluebird bioLentiglobin Program Leader and Head of Patient Operations2017 — 2019Cambridge, MA
  14. bluebird bioSenior Director, Technical Operations2015 — 2017Cambridge, MA
  15. Valeant PharmaceuticalsSenior Director, Commercial Technical Operations2015Greater Seattle Area
  16. DendreonSenior Director, Global Technical Operations2014 — 2015Seattle, Washington
  17. DendreonDirector, Global Technical Operations2011 — 2014Greater Seattle Area
  18. Zymogenetics (a wholly owned Bristol-Myers Squibb subsidiary)Head of Quality2010 — 2011
  19. ZymoGeneticsAssociate Director, Quality Assurance2009 — 2010
  20. ZymoGeneticsManager, QA Compliance2006 — 2009
  21. Gilead Sciences (fka Corus Pharma)Senior Quality Assurance Associate2004 — 2006
  22. Targeted GeneticsQuality Assurance Associate2003 — 2004
  23. Roche DiagnosticsSoftware Validation Quality Associate2002 — 2003
  24. BioMarin PharmaceuticalsClinical Manufacturing Associate2002
  25. Exelixis Inc.Assistant Research Scientist2001 — 2002

Skills & more

Biotechnology95Bioanalysis4Pharmacology6Strategic Planning26Analysis16Therapeutic Areas7FDA86Validation43GMP49Biopharmaceuticals25Pharmaceutical Industry54Forecasting3
+8 moreCAPACross-functional Team LeadershipProgram Management21 CFR Part 11TrainingMedical DevicesGLPContract Management
  • ASQ-CQA (Certified Quality Auditor) — American Society for Quality

From Peter's professional profile.

Frequently asked questions

Who is Peter Olagunju?
Peter Olagunju is CEO at a stealth-mode biotech company and serves as a board director. He has over 20 years of experience in clinical development, program management, manufacturing, quality management, and technical operations, spanning product types including small molecules, gene and cellular therapies, vaccines, recombinant proteins, monoclonal antibodies, and drug-device combinations. His work has contributed to advancing seven products from clinical development to commercialization, including ABECMA, ADSTILADRIN, LYFGENIA, PROVENGE, RECOTHROM, SKYSONA, and ZYNTEGLO.
Where did Peter Olagunju go to school?
Peter Olagunju studied at UW Foster School of Business (MBA, Business); University of Illinois Urbana-Champaign (Biology, Immunology).

Same school

Shared employers